Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

Biological Psychiatry

Volumn 59, Issue 3, 2006, Pages 216-223

  Keller, Martin ^a   Montgomery, Stuart ^b   Ball, William ^c   Morrison, Mary ^c   Snavely, Duane ^c   Liu, Guanghan ^c   Hargreaves, Richard ^c   Hietala, Jarmo ^d   Lines, Christopher ^c   Beebe, Katherine ^c   Reines, Scott ^c  

^a BROWN UNIVERSITY   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d TURKU PET CENTRE   (Finland)

Author keywords

Aprepitant; Clinical trial; Depression; Neurokinin1; Positron emission tomography; Substance P

Indexed keywords

APREPITANT; NEUROKININ 1 RECEPTOR; PAROXETINE; SUBSTANCE P ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NAUSEA; OUTPATIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SOMNOLENCE; STATISTICAL SIGNIFICANCE; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PERSONALITY INVENTORY; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NEUROKININ-1; REPRODUCIBILITY OF RESULTS; SUBSTANCE P; TREATMENT OUTCOME;

EID: 32144442187     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.07.013     Document Type: Article

References (26)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Association Washington, DC
2. M. Bergstrom, R.J. Hargreaves, D.H. Burns, M.R. Goldberg, D. Sciberras, S.A. Reines Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant Biol Psychiatry 55 2004 1007 1012
3. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2003 2290 2300
4. R. De Wit, P.J. Hesketh, D. Warr, K. Petty, A.D. Carides, J.K. Evans The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy A review Am J Cancer 4 2005 35 48
5. C.W. Dunnett, A.C. Tamhane A step-up multiple test procedure J Am Stat Assoc 87 1992 162 170
6. W. Guy ECDEU Assessment Manual for Psychopharmacology Publication ADM 76-338 1976 US Department of Health, Education, and Welfare Washington, DC
7. M. Hamilton The assessment of anxiety states by rating Br J Med Psychol 32 1959 50 55
8. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
9. 1) in the living human brain using positron emission tomography J Clin Psychiatr 63 suppl 11 2002 18 24
10. P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, R. de Wit The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group J Clin Oncol 21 2003 4112 4119
11. P.J. Hesketh, S. Van Belle, M. Aapro, F.D. Tattersall, R.J. Naylor, R. Hargreaves Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur J Cancer 39 2003 1074 1080
12. A. Holmes, M. Heilig, N.M.J. Rupniak, T. Steckler, G. Griebel Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends Pharmacol Sci 24 2003 580 588
13. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, J.J. Sramek Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
14. M.S. Kramer, A. Winokur, J. Kelsey, S.H. Preskorn, A.J. Rothschild, D. Snavely Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression Neuropsychopharmacology 29 2004 385 392
15. K.Y. Liang, S.L. Zeger Longitudinal data analysis of continuous and discrete response for pre-post designs Sankya Indian J Stat 62 2000 134 148
16. P.W. Mantyh Neurobiology of substance P and the NK1 receptor J Clin Psychiatry 63 suppl 11 2002 6 10
17. P.W. Mantyh, S.P. Hunt, J.E. Maggio Substance P receptors Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand Brain Res 307 1984 147 165
18. S. Poli-Bigelli, J. Rodrigues-Pereira, A.D. Carides, G. Julie Ma, K. Eldridge, A. Hipple Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 2003 3090 3098
19. A. Riberio-da-Silva, T. Hokfelt Neuroanatomical localisation of substance P in the CNS and sensory neurons Neuropeptides 34 2000 256 271
20. N.M.J. Rupniak New insights into the antidepressant actions of substance P (NK1 receptor) antagonists Can J Physiol Pharmacol 80 2002 489 494
21. L. Santarelli, G. Gobbi, P. Blier, R. Hen Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1) J Clin Psychiatry 63 suppl 11 2002 11 17
22. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller The Mini-International Neuropsychiatric Interview (M.I.N.I.) The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 59 Suppl 20 1998 22 33
23. O. Solin, O. Eskola, T.G. Hamill, J. Bergman, P. Lehikoinen, T. Grönroos Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK(1) receptor quantitation ([(18)F]SPA-RQ) Mol Imaging Biol 6 2004 373 384
24. M. Williams Hope springs eternal the importance of planning, serendipity and vision in clinical trial outcomes iDrugs 1 1998 887 889
25. D.F. Wong, A. Gjedde, H.N. Wagner Jr Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands J Cereb Blood Flow Metab 6 1986 137 146
26. D.F. Wong, A. Gjedde, H.N. Wagner Jr, R.F. Dannals, K.H. Douglass, J.M. Links Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity J Cereb Blood Flow Metab 6 1986 147 153